Search

everythinglearnresearchcommunity

for

Search:↓

Asparagus racemosus root extract reduced sebum and pore size in men but not in women.

New treatment improves male hair loss.

Ishophloroglucin A from Ishige okamurae may be a natural alternative for treating hair loss by inhibiting 5α-reductase and promoting hair growth.

Topical minoxidil and oral finasteride and dutasteride are the most effective treatments for male and female pattern hair loss, but study quality varies.

Lower growth factors linked to balding in androgenetic alopecia.

Differences in androgen receptor expression and tissue properties may lead to higher cryptorchidism risk in certain rats.

Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.

Plant-derived nanovesicles effectively deliver finasteride for hair regrowth in androgenetic alopecia.

Topical finasteride's effectiveness for hair loss needs standardized evaluation methods.

New drug strategies are needed for better hair loss treatments.

Vertex pattern hair loss linked to higher prostate cancer risk.

Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.

Finasteride effectively treats male hair loss, with oral and topical forms improving hair growth, but oral use may have side effects.

Certain adrenal hormones can strongly stimulate oil gland growth in hamster skin, similar to male hormones.

Men with early-onset baldness have a higher chance of heart disease and clogged arteries.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

cp-asiAR may effectively treat hair loss by targeting androgen receptors.

Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.

PON1 levels might indicate hair loss severity, but other health factors can affect this.

SM04554 may increase hair growth as a topical treatment for androgenetic alopecia.

A substance called prostaglandin D2 is linked to stopping hair growth in men with common baldness.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

TH07 is a topical combination of finasteride, latanoprost, and minoxidil, and shows promise.

Androgenetic alopecia is influenced by multiple genes and pathways, with genetic risk varying by population, and personalized treatments are being explored.

The document concludes that more research is needed on treatments for hair loss in both men and women, especially on medication combinations and their benefits.

Men with severe androgenetic alopecia, especially on the top of the head, have a higher risk of coronary artery disease.